Business
Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, Utah. To request a meeting with Senseonics, investo
About this update from Senseonics Holdings, Inc.
[{"type":"image","alt":"Senseonics Holdings, Inc.","displaySize":"","headline":null,"caption":"Senseonics Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":259,"height":48,"url":"https://media.zenfs.com/en/globenewswire.com/352de1d24c4134f17c1d3a538ac3ac2c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ta8zX_iGqe31qRhJe.4ZdQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/352de1d24c4134f17c1d3a538ac3ac2c","width":259,"height":48}},"lazy":false},{"type":"text","content":"GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, Utah.","length":458,"tagName":"p"},{"type":"text","content":"To request a meeting with Senseonics, investors should contact their BTIG representatives.","length":90,"tagName":"p"},{"type":"text","content":"About SenseonicsSenseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.","length":592,"tagName":"p"},{"type":"text","content":"Senseonics Investor ContactJeremy FefferLifeSci [email protected]","length":83,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"}]